AroCell AB: AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 2017

AroCell AB (publ) announces today that a research poster submitted by Jagarlamudi K.K. et al. entitled" AroCell TK 210 ELISA may complement pro PSA and the prostate health index in differentiating non-cancerous from cancerous conditions in prostate disease" has been accepted by the UK NICR for presentation at its annual meeting inNovember 5-8, 2017.

Thymidine kinase 1 (TK1) is a well-known cell proliferation biomarker. The purpose of this study was to compare the TK1 assayed with the AroCell TK 210 ELISA kit with PSA, free PSA, pro PSA and PHI (Prostate Health Index) in men with non-cancerous prostate conditions and patients with confirmed prostate cancer.

Serum samples with known PSA values from subjects investigated for prostate cancer were collected by the University Medical Centre, Ljubljana. Overall, AroCell TK 210 ELISA results showed significant correlation with PHI (r = 032, P = 0.0017) and pro PSA
(r = 021 P = 0.044) but not with free PSA or PSA. Combining the TK 210 value with the PHI or pro PSA value increased the diagnostic accuracy for prostate cancer compared with either individually.

CEO Jan Stålemark states "We are delighted that this preliminary study demonstrated that serum TK1 assayed with AroCell TK 210 ELISA kit can differentiate between non-cancerous conditions and prostate cancer patients with a similar accuracy to that of pro PSA or PHI. Further clinical studies will establish the capacity of AroCell TK 210 ELISA to complement pro PSA and PHI in distinguishing between non-cancerous and prostate cancer, potentially providing another tool in prostate cancer management".

This data was previously presented at the American Academy for Cancer Research Annual Meeting April 2017.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark,at 11.00 CET on 26 September 2017.

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure (Thymidine Kinase 1 (TK1) protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please seewww.arocell.com. Redeye AB is AroCell's Certified Adviser.